Bristol Myers Squibb expands AI drug-discovery partnership with Schrödinger

Bristol Myers Squibb's expanded Schrödinger partnership arrives at a critical juncture for the pharmaceutical company. The company faces substantial patent cliffs on blockbuster drugs Eliquis and Opdivo, creating urgency to accelerate its pipeline and refine molecule selection through computational efficiency. By deploying Bunsen's AI-driven physics-based modeling across its research organization, Bristol Myers Squibb is signaling confidence in AI's role in offsetting this revenue headwind—a move supported by its recent Q2 2026 financial performance, which showed revenue of US$12,973 million and net income of US$3,317 million, demonstrating the financial capacity to invest in next-generation platforms.

However, the partnership's incremental impact on R&D productivity does not materially alter Bristol Myers Squibb's near-term strategic imperative: replacing expiring blockbuster cash flows. Analysts remain divided on the company's ability to execute this transition. Consensus forecasts project $40.1 billion revenue and $8.6 billion earnings by 2029, with 6.2% annual revenue decline—implying an earnings boost of roughly $1.3 billion from current levels of $7.3 billion. Bearish analysts, by contrast, assume steeper 8% annual revenue declines and earnings near US$8.1 billion by 2029. This variance underscores that the real test of Bristol Myers Squibb's investment case lies not in incremental AI productivity gains, but in how successfully the company's pipeline fills the revenue gap left by patent expirations and pricing pressure.